Alemtuzumab is an anti-CD52 monoclonal antibody that was initially approved by the FDA in 2001 for B-cell chronic lymphocytic leukemia (B-CLL) (6). The gene discussed is CD52; the disease is B-cell chronic lymphocytic leukemia.